|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Haemonetics Corporation HAE, a global manufacturer of automated blood processing systems. |
|---|---|
| Transferring Party | Haemoscope Corporation, a provider of whole blood hemostasis monitoring systems. |
| Sector | Medical Services |
| Date | October 30, 2007 |
| Analysis Haemoscope's systems can predict a patient's risk of bleeding and thrombotic complications and enable personalized therapy. With this knowledge, surgeons can plan a patient's treatment and hospitals can reduce their need for blood transfusions by 20% or more annually. More than 1900 units have been placed worldwide. The deal strengthens Haemonetics as a leader in blood management solution and fits well with its recent Infonale acquisition. Deal value $44m, on sales of $16m growing at 15% annually. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |